Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

SS) PER COMMON SHARE Basic $ 0.01 $ (0.15) $ 0.32 $ (1.11) ============================================ Diluted $ 0.01 $ (0.15) $ 0.31 $ (1.11) ============================================ SHARES USED IN COMPUTING NET INCOME (LOSS) PER COMMON SHARE Basic 47,932,029 45,222,053 47,880,737 44,348,537 ============================================ Diluted 49,028,254 45,222,053 48,326,718 44,348,537 ============================================ Balance Sheet Information: September 30, 2009 December 31, 2008* ------------------ ------------------ (unaudited) Cash, cash equivalents, interest Receivable and short-term investment securities $33,687 $15,467 Long-term investment securities 7,333 7,185 Total assets 45,458 26,634 Accumulated deficit (316,775) (331,918) Stockholders' equity (deficiency) 34,959 (1,489) * Condensed from audited financial statements.

SOURCE Keryx Biopharmaceuticals, Inc.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... Calif. , July 10, 2014  Breg, ... and services, has launched the FreeRunner™ knee brace ... who suffer from patella mal-tracking return to active ... differently than other braces, providing support when patients ... normally when they don,t. Patellofemoral issues ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
(Date:7/10/2014)... Denver, CO (PRWEB) July 11, 2014 ... Vicki Cowart, President and CEO of Planned Parenthood of ... the fact Senator Mark Udall and Representative Diana DeGette ... the Supreme Court’s Hobby Lobby decision and keeping bosses ... and PPRM representatives listened to the president today in ...
(Date:7/10/2014)... 11, 2014 The Capital Institute for ... the first procedure in a clinical trial that delivers ... the leg. , During the procedure, done at Capital ... endovascular neurosurgeon, threaded a tiny catheter through the patient’s ... and neck and into the brain. Once the catheter ...
(Date:7/10/2014)... Mice consuming a supplement of omega 3 fatty acids ... saturated fats and omega 6 fatty acids, according to ... Annals of the Rheumatic Diseases (10.1136/annrheumdis-2014-205601) on ... not just obesity may contribute to worsening osteoarthritis. ... more significant role than mechanical factors in the link ...
(Date:7/10/2014)... 2014 More than 200 experts on ... urban street violence, will attend the 21st World Meeting ... (ISRA) at the Loews Atlanta Hotel, July 15-19. ... prestigious world meeting, which is held every other year ... bringing together leading scholars from more than 20 different ...
(Date:7/10/2014)... Fatigue, lack of safety equipment and ... accidents in the workplace, according to a series ... safety issues that contribute to the alarming workplace ... the job annually, according to the International Labor ... workplace accidents." , Safety Issue: "Extended Work Hours ...
Breaking Medicine News(10 mins):Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3
... 7 Vion,Pharmaceuticals, Inc. (Nasdaq Capital Market: VION) ... that the Company had regained,compliance with Marketplace Rule ... Stock had traded at $1.00 per share or ... Vion Pharmaceuticals, Inc. is committed to extending the ...
... MGT Capital Investments,Inc. (Amex: MGT ), ... ("HCIT") sector, today commented on the American Cancer,Society,s ... its colon cancer screening guidelines. MGT Capital Investment,s,Medicsight ... exchange under,"MDST," is an industry leader in the ...
... March 7 Novavax, Inc.,(Nasdaq: NVAX ) a ... and Chief Executive Officer, will be presenting at,the Partnering ... on March 11,2008 in Washington D.C. Dr. Singhvi will ... the area of vaccine development to,protect against H5N1 pandemic ...
... Calif., March 7 Genoptix, Inc.,(Nasdaq: GXDX ), ... in the 11th Annual Lehman Brothers Global,Health Care Conference ... Fla.,March 18 - 20, 2008., Dr. Tina Nova ... will present at the conference on Tuesday, March 18, ...
... to protect its Intellectual Property that, has been employed in Minimally Invasive ... ... decade, MARIETTA, Ga., March 7 In a much anticipated decision,Judge ... personally liable for expenses and attorneys,fees incurred by ERBE while defending against ...
... Liverpool School of Tropical Medicine has received a $30 million ... the control and treatment of malaria in pregnancy in Africa, ... directly benefit the 50 million women who face exposure to ... research at Liverpool and at 38 partner institutions in 27 ...
Cached Medicine News:Health News:Vion Pharmaceuticals Regains NASDAQ Listing Compliance 2Health News:MGT Comments on American Cancer Society's Decision to Endorse CT Colonography 2Health News:MGT Comments on American Cancer Society's Decision to Endorse CT Colonography 3Health News:MGT Comments on American Cancer Society's Decision to Endorse CT Colonography 4Health News:Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference 2Health News:ERBE Perseveres Yet Again in Opposition to Dr. Jerome Canady, and is Awarded More Than One Million Dollars 2Health News:LSTM to lead $30 million research program into malaria in pregnancy 2
... a Q-switched ruby laser system ... nm. High Performance Combined with ... combination of high performance and ... mode effectively destroys the (natural ...
... The NMP22 BladderChek Test is the only ... diagnosis of bladder cancer. The NMP22 BladderChek Test ... a single urine sample, that detects elevated levels ... small amounts of NMP22 protein in the urine. ...
... The NMP22® Test Kit is a quantitative ... NMP22 protein. Healthy individuals generally have very small ... the level of NMP22 protein is often elevated ... even at early stages of the disease. The ...
... cystometry and urethral pressure profilometry. The ... bladder to be filled while cystometry ... the catheter in the bladder for ... is standing or sitting. Supplied sterile ...
Medicine Products: